in Celcuity. Thank you, interest Maria, and your everyone. good appreciate afternoon, We
second the to of VIKTORIA-X, continues remains wild-type XXXX. III trial, to the top well. data Our track half proceed PIKXCA Phase report line subgroup in on for Enrollment
million wild-type Achieving first right from enrollment gave our facility, debt our an with than threshold during $XX down XX% quarter, current the tranche we enrolled. During update this in conjunction more the reported us draw additional the that was to an facility. debt subgroup to quarter the related first
lines treatment. inhibitor. HERX-negative progressed a And second median while inhibitor these and But months have cancer receiving on in CDKX/X aromatase we're advanced study received an typically CDKX/X for if first of XX up endocrine eligible HR-positive letrozole patients that enrollment The with X the treatment a evaluating they've breast for of enrolled prior patients to those this And their remain treatment. are line XX whose disease be on receiving anticipate depending regimen patients of most inhibitor CDKX/X we will inhibitor. plus line to
And to treatment arm fulvestrant. and of this that comparable XX palbociclib reported months with medium for Ib cancer the evaluated Phase enrolled in our compares duration combined prior breast study the patients of gedatolisib
the is for worse III prognosis compared cancer our eligible received study, since who setting who the individuals previously prior Ib breast and chemotherapy comparable have who our not for relevant in advanced advanced for are undergone Phase tends those are to the of chemo Patients study, chemo-naive. this to unlike Phase arm be
will have difference in Phase the disease. roughly the Phase is eligibility III allowance relative bone-only other of trials, that the from bone-only our Phase patients criteria study study with Phase XX% in on Another data III Ib expect Based enrolled of to patients we disease. III our
in received Our not correlate worse worse bone-only have disease, enrolled. disease have visceral than only bone-only in who setting that Ib eliminating this with study with Phase Phase And with patients prognosis with patients, and we're those advanced allowing not our relevant non-bone-only generally patients by those study allow bone-only By outcomes. those did with factors including prior chemotherapy III since the disease is disease. were X
position future to potential in gedatolisib's we a take account for the preparing treatment begin into landscape, select will use the therapy. criteria we As oncologists cancer
advanced motive breast administration. then are safety recommendations, importance And efficacy not based safety of mode consistent then order preference, in is which and cancer. criteria especially on with considerations, these think this efficacy, in of We are guideline administration
X treatment current SERDs, or as approved with like agents ER-positive for or with fulvestrant patients or inhibitors fulvestrant. paradigm breast elacestrant X The or single estrogen cancer second-line degraders receptor of advanced HERX-negative PAM selective combined
of nodes, as because or compensatory is can AKT the alpha, PAM PAM a PAM induce uninhibited such each only which mTORCX, single targets PIXK the However, nodes suboptimal inhibitors resistance.
have treatment none In with wild-type inhibitor, a have patients drugs CDKX/X of who patients PIKXCA tumors. demonstrated who received efficacy in prior these have
in data node X with inhibitor While have alpha gedatolisib. the less efficacy only than the those Xx are shows cells these cancer consistent This nonclinical breast PIXK sharp with reported single and in PIKXCA the data with and patients results inhibitors potent AKT in nonclinical to without for mutations to PIKXCA are reported And in mutations. contrast we've that benefit these preliminary them. is
gedatolisib In and breast cancer and cells was lines, in least potent and to prostate found without efficacious more mutations cancer and in breast potent on equally studies the lines at cell inhibitors. cell PIKXCA cancer single-node average XXXx PAM with improved be evaluating than
we that's the think evaluated driver reported presence estrogen that of with study combined palbociclib plays HR-positive we in breast Ib advanced a the either these like these from pathway as results HERX-negative activating intrinsic comparable an with and patients demonstrate CDKX/X treatment-naive independent or efficacy in was pathways, PAM in PIKXCA. disease third-line breast an cancer, Consistent mutation receptor that and role second without along with And the PIKXCA Phase mutations. and results, nonclinical our gedatolisib fulvestrant letrozole both and with preliminary cancer
And I PAM opportunities most breast to represents the that's in development mTORCX why we X of the that and inhibitor of improve and like HERX-negative PIXK targets care standard isoforms, important advanced one Class believe cancer. all optimized of gedatolisib HR-positive, an
benchmarks will surge alpha potential pretreated meaningful The patients for with Published reports mutations, benefit. and range inhibitor for the clinically gedatolisib's of from PFS And MPFS foundation the CDKX/X for months PFS the a to require X.X X.X median are modest. a median current respectively. the patients of future in report AKT PIKXCA gedatolisib PIXK positioning, obviously, X inhibitors, to X.X months. with Now
generally population patient PFS for consider reported be this approved months to X The clinically meaningful. KOLs therapies to The two of incremental threshold X.X most recently benefit.
addition, backbone And exhausted. oncologists from consistently lately this delay benefit actually ADCs use perspective that was of heard by is or prefer to regimens chemotherapy In recently from echoed until the we've endocrine from an characterized landscape third based sits management ADC HR-positive, breast and therapy treatment chemotherapy. for is senior between that HERX-negative endocrine classical ADCs pillar That regimens creating the in cancer. a sponsor
these an comments breast includes AKT drug And inhibitor. of in are SERD with the development sponsor's development and strategy consistent cancer, which oral
landscape. discontinuation to for profile rates Ib schedule, fulvestrant to comparable discontinuation intermittent may which its think the positioning treatment-related dose arm in future Phase Gedatolisib's We plus was favor a only III rate regimens. treatment X% also is CDKX/X Phase in gedatolisib's the safety with X% the X% potential
favorably Since everolimus treatment-related compare reported discontinued. alpelisib plus results the study patients further prophylactic trial, these exemestane, given for XX% results of of prophylactic discontinuation XX% events, receive profile. stomatitis get which And discontinued related and for promising III in prescribing studies to patients expect stomatitis. we're Phase we Ib [indiscernible] our that not encouraging in where enhance Phase gedatolisib's III already plus or the would adverse The rates treatment safety did in patients the specially stomatitis Phase we would fewer fulvestrant
significant to therapies, gedatolisib. orally There convenience the offers a Otherwise, well-tolerated And such profile more a from of are distance be to the treatment like that meaningful as will therapy relative when one clinically several benefit by meaningful therapy, convenient. when patient a site. infused a overwhelmingly efficacy, comparable oncologists lives advantages is that is setting, key are efficacy finally, alternative real-world offers In drugs an and consideration only a a the preferred less or relative office-administered or self-administered PFS drugs. safety in but
category. this medical the a into into has fall benefit several far implications. process gedatolisib administered than benefit pharmacy as which such fall orally category, streamlined therapies, has reimbursement more Office-administered which drugs, the And
costs recover additional can associated patients. treating oncologists our with First,
to Second, and is oncologists payer much burdensome. management autonomy select process have less more therapies
the payer price third, results less company. contracting fewer for which And pharmaceutical in frequent, is discounts
out-of-pocket costs therapy, And fourth, typically is consideration important which an an patients. incur patients for infused most with lower
Phase for evaluating AR prostate This with inhibitor. Beyond combination metastatic trial February, our patients to an cancer or darolutamide, previously an CRPC in breast patient in opportunity a in about treated our cancer, Ib/II receptor excited we're gedatolisib patients dosed inhibitor develop gedatolisib castration-resistant we androgen CRPC. first past program, with with the
PAM cancer which showed both plays HR-positive nonclinically prostate The been Like cancer cancer, clinical PAM well studies. involves has and proof-of-concept breast role inhibitors, pathway in characterized in pathway. PAM data a continued that randomized the pathway compelling hormonal [indiscernible] and prostate trial X in X
clinical inhibitor control inhibitors is of In the benefit patients significantly these the these with in trials encouraging is meaningful than efficacious CRPC. arm each more gedatolisib especially was receptor clinically in This potent PAM relative inhibitors, and PAM reported treatment vitro. since androgen for to other
darolutamide gedatolisib. assessment and of Ib Primary portion of objectives II of of tolerability the of and with Phase include gedatolisib recommended safety dose the in of trial combination the the determination Phase
the that, over in And We Officer, results. half anticipate I'll data reporting Vicky to Chief our now to first Financial Hahne, of initial financial XXXX. review turn our call preliminary the with
